surmount-1 tirzepatide non-diabetic obesity trial Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials | Advances in Therapy Effect of tirzepatide in SURMOUNT-1

This preserves the body's natural regulatory mechanisms and may have implications for long-term hormonal health, though comparative long-term studies are limited

Tirzepatide is taken once weekly as an injection, and the day of the week matters more than the time of day

Geniposide, acting as a GLP-1R agonist, partially prevented STZ-induced learning and memory impairment via modulation of PI3K/GSK-3 signaling pathway and reduced STZ-induced hyperphosphorylation of tau protein (220)

Methods Trial Design Both trials were randomised, open-label, parallel-group, single-centre (Parexel, Berlin, Germany) trials (Fig

The lowest dose of tirzepatide (5 mg) reduced A1C by 2.09 percent and body weight by 7.8 kg (17.2 lb., 8.5 percent) compared to semaglutide at 1.86 percent and 6.2 kg (13.7 lb., 6.7 percent)

FDA shortage status Compounded tirzepatide is legally available in the United States because the FDA has listed branded tirzepatide (Zepbound and Mounjaro) on its drug shortage list